NGM Bio Reports Topline Results from 24-Week Phase 2b ALPINE 2/3 Study of Aldafermin in NASH
May 24, 2021 07:00 ET
|
NGM Biopharmaceuticals, Inc.
Study did not meet primary endpoint of fibrosis improvement by >1 stage with no worsening of NASH versus placeboStatistical significance achieved versus placebo on certain secondary endpoints,...
NGM Bio to Host Conference Call to Discuss Topline Results from 24-Week Phase 2b ALPINE 2/3 Study of Aldafermin in NASH
May 23, 2021 18:00 ET
|
NGM Biopharmaceuticals, Inc.
SOUTH SAN FRANCISCO, Calif., May 23, 2021 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (Nasdaq: NGM) will host a conference call and live webcast on Monday, May 24, 2021 at 8:30 a.m. ET (5:30...
NGM Bio Provides Business Highlights and Reports First Quarter 2021 Financial Results
May 06, 2021 16:05 ET
|
NGM Biopharmaceuticals, Inc.
Expect to report topline data from Phase 2b ALPINE 2/3 clinical trial of aldafermin in patients with NASH with F2 and F3 liver fibrosis in the second quarterContinued enrollment in Phase 2 CATALINA...
NGM Announces Nomination of Roger M. Perlmutter for Election to Its Board of Directors
April 28, 2021 16:15 ET
|
NGM Biopharmaceuticals, Inc.
SOUTH SAN FRANCISCO, Calif., April 28, 2021 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative...
NGM Bio Provides Business Highlights and Reports Fourth Quarter and Full Year 2020 Financial Results
March 04, 2021 16:05 ET
|
NGM Biopharmaceuticals, Inc.
•Significant progress made across liver and metabolic diseases, retinal diseases and cancer during fourth quarter 2020: •Presented first-in-human results from Phase 1 clinical trial of NGM621 in...
NGM Bio Initiates Expansion of Ongoing Phase 1b Proof-of-Concept Study of NGM120 in Patients with Metastatic Pancreatic Cancer
March 02, 2021 08:00 ET
|
NGM Biopharmaceuticals, Inc.
--Placebo-controlled study to evaluate potential of NGM120, a novel inhibitor of GDF15/GFRAL pathway, to treat cancer and cancer-related cachexia-- --Cachexia, a wasting syndrome, is a common...
NGM Bio to Present at the Cowen 41st Annual Health Care Conference
February 25, 2021 08:00 ET
|
NGM Biopharmaceuticals, Inc.
SOUTH SAN FRANCISCO, Calif., Feb. 25, 2021 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative...
NGM Bio Announces Upcoming Oral Presentation of Phase 1 Study of NGM621 in Patients with Geographic Atrophy at Angiogenesis, Exudation, and Degeneration 2021 - Virtual Edition
February 09, 2021 08:00 ET
|
NGM Biopharmaceuticals, Inc.
--Humanized IgG1 monoclonal antibody engineered to potently inhibit complement C3, with the potential for extended every eight-week dosing-- --CATALINA Phase 2 study of NGM621 in patients with...
NGM Bio Outlines 2021 Strategic Priorities Across Its Three Therapeutic Area Portfolios, Including Liver and Metabolic Diseases, Retinal Diseases and Oncology
January 12, 2021 16:05 ET
|
NGM Biopharmaceuticals, Inc.
NGM advances its vision to build the next iconic biologics company, fueled by its in-house discovery engineSignificant progress made across all three therapeutic area portfolios in 2020Phase 2b or...
NGM Bio Announces Pricing of Upsized $125.0 Million Public Offering of Common Stock
January 05, 2021 21:55 ET
|
NGM Biopharmaceuticals, Inc.
SOUTH SAN FRANCISCO, Calif., Jan. 05, 2021 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative...